Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Renovaro Inc (RENB)

Renovaro Inc (RENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 224,122
  • Shares Outstanding, K 143,668
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,680 K
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.62
Trade RENB with:

Options Overview Details

View History
  • Implied Volatility 236.70% ( -131.42%)
  • Historical Volatility 96.70%
  • IV Percentile 71%
  • IV Rank 31.50%
  • IV High 634.16% on 10/20/23
  • IV Low 53.90% on 10/10/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 76
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,042
  • Open Int (30-Day) 1,245

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +27.42%
on 04/29/24
3.0500 -48.20%
on 04/01/24
-1.0700 (-40.38%)
since 03/28/24
3-Month
1.2400 +27.42%
on 04/29/24
4.4500 -64.49%
on 02/06/24
-2.8000 (-63.93%)
since 01/30/24
52-Week
0.3928 +302.24%
on 06/29/23
5.2500 -69.90%
on 01/25/24
+0.4400 (+38.60%)
since 04/28/23

Most Recent Stories

More News
Renovaro BioSciences (NASDAQ: RENB) Announces Results of Special Meeting

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held...

RENB : 1.5800 (+1.28%)
Renovaro BioSciences (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released...

NVDA : 864.02 (-1.54%)
RENB : 1.5800 (+1.28%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Featured in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured...

RENB : 1.5800 (+1.28%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Poised to Spearhead Advancements in Battle Against Diseases

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, recently announced a definitive agreement to combine with the advanced AI company GEDiCube...

INTC : 30.47 (-2.84%)
RENB : 1.5800 (+1.28%)
Renovaro BioSciences (NASDAQ: RENB) Eyes Opportunity in Precision Medicine Market

Renovaro BioSciences (NASDAQ: RENB), an advanced, preclinical biotechnology company, and GEDi Cube Intl Ltd., an AI medical technology company, previously announced a definitive agreement to combine. The...

RENB : 1.5800 (+1.28%)
Unlocking AI investment opportunities in healthcare

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

INTC : 30.47 (-2.84%)
NVDA : 864.02 (-1.54%)
RXRX : 7.82 (-4.63%)
RLAY : 6.52 (-1.06%)
EXAI : 4.95 (+7.14%)
RENB : 1.5800 (+1.28%)
BTAI : 2.52 (-2.33%)
Renovaro Biosciences (NASDAQ: RENB) CEO Provides Update on Combination with GEDiCube

In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced...

RENB : 1.5800 (+1.28%)
Renovaro BioSciences (NASDAQ: RENB), GEDi Cube Combine to Transform Medicine Through AI, Biotherapeutics

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell and immunotherapy platforms that modulate immune responses against cancers and...

RENB : 1.5800 (+1.28%)
Renovaro Biosciences (NASDAQ: RENB) Adds Three New Members to Board as Definitive Agreement with GEDiCube Announced

Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement...

RENB : 1.5800 (+1.28%)
Renovaro BioSciences (NASDAQ: RENB) CEO Provides Insights on Agreement to Combine with GEDi Cube

Renovaro BioSciences (NASDAQ: RENB), a preclinical biotechnology company involved in the development of enhanced gene, cell, and immunotherapy platforms that modulate immune responses against cancers and...

NVDA : 864.02 (-1.54%)
RENB : 1.5800 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Renovaro Inc. includes RenovaroCube and Renovaro Biosciences. Renovaro Biosciences is an advanced cell-gene-immunotherapy company. Its lead candidate product is a therapeutic vaccine targeting cancers which are difficult to treat including pancreatic and potentially HNC, triple-negative breast cancer,...

See More

Key Turning Points

3rd Resistance Point 2.1200
2nd Resistance Point 1.9800
1st Resistance Point 1.7800
Last Price 1.5800
1st Support Level 1.4400
2nd Support Level 1.3000
3rd Support Level 1.1000

See More

52-Week High 5.2500
Fibonacci 61.8% 3.3945
Fibonacci 50% 2.8214
Fibonacci 38.2% 2.2483
Last Price 1.5800
52-Week Low 0.3928

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar